# Real World Adherence of PCSK9 Targeted Therapy

> **NCT07468500** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 3600 (estimated)

## Conditions studied

- Dyslipidemia, Hypercholesterolemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07468500
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 3600 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468500, "Real World Adherence of PCSK9 Targeted Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07468500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*